Senti Biosciences
Senti Biosciences
SNTI
NASDAQ
3.64
USD
4.30%
About
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells.
Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 38.7K |
| Three Month Average Volume | 16.0M |
| High Low | |
| Fifty-Two Week High | 8.479 USD |
| Fifty-Two Week Low | 1.5201 USD |
| Fifty-Two Week High Date | 09 Nov 2023 |
| Fifty-Two Week Low Date | 07 Aug 2024 |
| Price and Volume | |
| Current Price | 2.65 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 21.77% |
| Thirteen Week Relative Price Change | -17.47% |
| Twenty-Six Week Relative Price Change | -44.08% |
| Fifty-Two Week Relative Price Change | -67.46% |
| Year-to-Date Relative Price Change | -66.09% |
| Price Change | |
| One Day Price Change | -2.21% |
| Thirteen Week Price Change | -11.67% |
| Twenty-Six Week Price Change | -38.52% |
| Five Day Price Change | -8.30% |
| Fifty-Two Week Price Change | -59.23% |
| Year-to-Date Price Change | -59.85% |
| Month-to-Date Price Change | 14.72% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 14.64173 USD |
| Book Value Per Share (Most Recent Quarter) | 9.65526 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 14.64173 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 9.65526 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -13.71726 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.57716 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.07488 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -18.79689 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -17.51731 USD |
| Normalized (Last Fiscal Year) | -12.94594 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -18.79689 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -17.51731 USD |
| Including Extraordinary Items (Last Fiscal Year) | -16.01407 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -12.64606 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 7.86123 USD |
| Cash Per Share (Most Recent Quarter) | 3.46862 USD |
| Cash Flow Per Share (Last Fiscal Year) | -17.99437 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -16.45269 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -9.81814 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -13,112 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -23,259.47% |
| Pretax Margin (Last Fiscal Year) | -3,256.78% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -3,620.73% |
| Operating Margin (Trailing Twelve Months) | -27,287.28% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -3,256.78% |
| Net Profit Margin (Trailing Twelve Months) | -23,259.47% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -91.65% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 65.40% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 23.86% |
| EPS Change (Trailing Twelve Months) | -35.15% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -15,759,000 |
| Net Debt (Last Fiscal Year) | -35,829,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5 |
| Price to Sales (Trailing Twelve Months) | 36 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -64,433,000 |
| Free Cash Flow (Trailing Twelve Months) | -44,320,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -55.55% |
| Return on Assets (Trailing Twelve Months) | -68.20% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -85.91% |
| Return on Equity (Trailing Twelve Months) | -111.07% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -61.89% |
| Return on Investment (Trailing Twelve Months) | -74.50% |
| Return on Investment (5 Year) | -99,999.99% |